Drug: Enasidenib (Idhifa, Celgene)
Status: Approved to treat adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) who have the isocitrate dehydrogenase-2 (IDH2) mutation. The drug is approved for use with a companion diagnostic, the RealTime IDH2 Assay (Abbott Laboratories).